High Evidence
Research Overview
Liraglutide Research for Cardiovascular Disease
An evidence-based overview of research examining Liraglutide in the context of cardiovascular disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
LEADER trial demonstrated 13% reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) and 22% reduction in cardiovascular death in adults with T2D at high CV risk. Victoza's FDA label includes major adverse CV event reduction for adults with T2D and established CV disease; Saxenda does not carry that indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.